Keyword: Paul Chaplin

The J.P. Morgan Healthcare Conference was a great place to suss out the general biopharma mood as 2018 begins.

After a major cancer vaccine misstep, Bavarian Nordic reported positive six-week data from an ongoing phase 2 study on its RSV vaccine candidate.

Chasing a $6 billion market opportunity, Bavarian Nordic reports that a dose of its universal RSV vaccine can elicit a significant immune response.